SecBot SecBot

SVA

SINOVAC BIOTECH LTD
Nasdaq· Pharmaceutical Preparations· Inc. B9· CIK 0001084201 Biotech & Drug Discovery
—
Median target
$3.40
range $1.50–6.00
Short interest
82.2K
0.0%
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 1 report · 90 days
Balance 1 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest BEARISH Sinovac reported H1 2026 unaudited results: sales grew 12.9% YoY to $147.1M, driven by 82.3% overseas…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest 0.0% to 82.2K shares.

The Street

last action Mar 2014
Recent actions
DateFirmActionRating
Mar 20, 2014Morgan Stanley
UPGRADE
UPGRADEOverweight
Nov 13, 2013Aegis Capital
MAINTAIN
MAINTAINBuy
Aug 15, 2013Aegis Capital
UPGRADE
UPGRADEBuy
May 15, 2013Morgan Stanley
UPGRADE
UPGRADEEqual-Weight
Mar 14, 2013Aegis Capital
MAINTAIN
MAINTAINHold
Dec 12, 2012Aegis Capital
INITIATE
INITIATEHold

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Next Q$0.00$0.00–$0.00—$0.0B
+5y$0.00$0.00–$0.00——
Current Q$0.00$0.00–$0.00—$0.0B
-5y$0.00$0.00–$0.00——
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 23, 2026
Clinical Trial
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
Phase Phase 3 — COMPLETED
Jun 26, 2026
Clinical Trial
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
Phase Phase 2 — COMPLETED
Jun 3, 2026
Clinical Trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
Phase Phase 2 — COMPLETED
May 21, 2026
Trial readout
Results Pending: Sinovac Low-dosage PCV24 (Phase 2) — Completed 84d ago
Trial: Clinical Trial of PCV24 in Adults Aged ≥18 Years Sponsor: Sinovac Life Sciences Co., Ltd. Phase: Phase 2 | Completed: 2026-02-26 Conditions…
Apr 21, 2026
Trial readout
Results Pending: Sinovac Low-dosage PCV24 (Phase 2) — Completed 54d ago
Trial: Clinical Trial of PCV24 in Adults Aged ≥18 Years Sponsor: Sinovac Life Sciences Co., Ltd. Phase: Phase 2 | Completed: 2026-02-26 Conditions…

Short side

FINRA· Sep 30, 2026
82,156
shares short
0.0%
vs prior settlement
Trading halts
Feb 22, 2019Info RequestedNot resumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 17, 2026 SEC
Sinovac reported H1 2026 unaudited results: sales grew 12.9% YoY to $147.1M, driven by 82.3% overseas revenue growth…
6-K — Impact 6/10
Jul 15, 2026 SEC
Sinovac Biotech announced a further extension of the deadline for shareholders to submit payment instructions for its…
6-K — Impact 2/10
Jun 15, 2026 SEC
Sinovac regained Nasdaq listing compliance following the long-delayed filing of its FY2025 20-F on June 5, 2026, which…
6-K — Impact 6/10
May 21, 2026 Clinical trial readout
Results Pending: Sinovac Low-dosage PCV24 (Phase 2) — Completed 84d ago
Trial: Clinical Trial of PCV24 in Adults Aged ≥18 Years Sponsor: Sinovac Life Sciences Co., Ltd. Pha

SecBot reports

7 filings · 0 bullish · 5 bearish · 2 neutral
All SVA filing & press-release reports (7)